UCLA has launched a patient-centered institute dedicated to developing therapies for the treatment of kidney, bladder, testicular, and prostate cancers.
UCLA has launched a patient-centered institute dedicated to developing therapies for the treatment of kidney, bladder, testicular, and prostate cancers.
The Institute of Urologic Oncology at UCLA challenges the traditional model of academic departments operating independently of each other, bringing a multidisciplinary team of scientists and physicians together as part of one organization, according to a UCLA statement. The goal is to expedite the development of new therapies for patients with genitourinary cancers.
The disciplines represented at the institute include urologic oncology, medical oncology, diagnostic and interventional radiology, pathology, nursing, basic sciences, and clinical trials. The new institute will allow experts from these areas to collaborate toward advances in medical and surgical treatments, including targeted therapies, chemotherapy, immunotherapy, radiation therapy, and minimally invasive and ablative surgery.
“This is a one-stop shop for patients. All the experts will be involved in their care, all working together,” said Arie Belldegrun, MD, the institute’s new director and professor of urology at UCLA’s Jonsson Comprehensive Cancer Center. “Our goal is to bring all our resources to the patient, rather than the patient going from office to office to see everyone they need to see.”
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.